



Newsletter from Emotra AB (publ)

Göteborg, November 18, 2015

Presentation of Emotra and EDOR at Stora Aktiedagen

A presentation of the company Emotra will be held at the Stora Aktiedagen exhibition in Göteborg, Sweden, on November 23, between 8:20 and 9:00 am. You can follow the presentation via a live broadcast.

During Stora Aktiedagen, which is being held at the Swedish Exhibition & Congress Centre in Göteborg, Emotra's CEO will be holding a presentation of the company and its EDOR method for assessment of suicide risk. He will also be presenting the planned market launch and the company's chosen strategies.

During his presentation, Emotra's CEO will also state that more than 1,100 patients have so far been tested using EDOR in the company's ongoing, clinical multi-centre study in Europe.

Use the following link to view Emotra's presentation:

www.aktiespararna.se/livesandning

Scroll down to the schedule for **Room E3!**

For further information about the Company, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, www.emotra.se